尿L-FABP是失代偿期肝硬化患者ACLF和死亡预后的候选生物标志物
该前瞻性研究纳入444例因失代偿期肝硬化住院的患者,分为研究队列305例和验证队列139例,检测入院时尿和血浆L-FABP及尿NGAL。多因素分析显示尿L-FABP和MELD-Na是预后的独立预测因素,尿L-FABP可预测ACLF发生和3个月生存,并在验证队列中确认。
要点
- 尿L-FABP与失代偿期肝硬化患者3个月生存相关,血浆L-FABP无此关联
- 尿L-FABP和MELD-Na是预后的独立预测因素
- 尿L-FABP可预测ACLF发生,并在验证队列中确认
核心结论
- 尿L-FABP水平与失代偿期肝硬化患者3个月死亡和ACLF发生独立相关,是候选预后生物标志物。
研究设计与样本
- 前瞻性系列纳入444例因失代偿期肝硬化住院的患者,分为研究队列305例和验证队列139例,检测入院时尿和血浆L-FABP及尿NGAL。
主要发现
- 单因素分析中尿L-FABP而非血浆L-FABP与3个月生存相关。
- 多因素分析中尿L-FABP和MELD-Na是仅有的独立预后预测因素。
- ACLF患者尿L-FABP水平高于无ACLF者,且尿L-FABP联合MELD-Na可预测随访期间ACLF发生。
- 在ACLF患者中,尿L-FABP与肝脏、凝血和循环衰竭相关。
- 急性肾损伤患者尿L-FABP水平升高,尤其急性肾小管坏死患者。
临床怎么用
- 对于失代偿期肝硬化住院患者,可检测入院时尿L-FABP以辅助评估3个月死亡和ACLF发生风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Decompensated cirrhosis (DC) is associated with high mortality, mainly owing to the development of acute-on-chronic liver failure (ACLF). Identifying the patients with DC who are at high risk of mortality and ACLF development is an unmet clinical need. Liver fatty acid-binding protein (L-FABP) is expressed in several organs and correlates with liver and systemic inflammation. Herein, we aimed to assess the prognostic value of L-FABP in patients with DC. METHODS: A prospective series of 444 patients hospitalized for DC was divided into 2 cohorts: study cohort (305 patients) and validation cohort (139 patients). L-FABP was measured in urine and plasma samples collected at admission. Neutrophil gelatinase-associated lipocalin (NGAL) was also measured in urine samples for comparison. RESULTS: Urine but not plasma L-FABP correlated with 3-month survival on univariate analysis. On multivariate analysis, urine L-FABP and model for end-stage liver disease (MELD)-Na were the only independent predictors of prognosis. Urine L-FABP levels were higher in patients with ACLF than in those without and also predicted the development of ACLF, together with MELD-Na, during follow-up. In patients with ACLF, urine L-FABP correlated with liver, coagulation, and circulatory failure. Urine L-FABP levels were also increased in patients with acute kidney injury, particularly in those with acute tubular necrosis. The ability of urinary L-FABP to predict survival and ACLF development was confirmed in the validation cohort. Urine NGAL predicted outcome on univariate but not multivariate analysis. CONCLUSIONS: Urinary L-FABP levels are independently associated with the 3-month clinical course in patients with DC, in terms of mortality and ACLF development. Urinary L-FABP is a promising prognostic biomarker for patients with DC. LAY SUMMARY: Increased levels of liver fatty acid-binding protein (L-FABP), a protein related to lipid metabolism, have been associated with liver-related diseases. The present study analyzed urinary L-FABP levels in 2 independent groups of patients with decompensated cirrhosis and showed that higher urinary L-FABP levels correlated with increased mortality and risk of acute-on-chronic liver failure development. Therefore, urinary L-FABP levels could be useful as a new tool to predict complications in patients with decompensated cirrhosis.
引用
- Juanola A, Graupera I, Elia C, et al. Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. J Hepatol. 2021. PMID: 34530063. doi:10.1016/j.jhep.2021.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。